New combination drug approaches for neuroendocrine prostate cancer
Developing New Treatment Strategies for Neuroendocrine Prostate Cancer
This work seeks to use combinations of drugs that block specific proteins to treat people with aggressive neuroendocrine prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11322632 on NIH RePORTER |
What this research studies
I have neuroendocrine prostate cancer and researchers are studying how loss of the tumor-suppressor genes TP53 and RB1 makes the cancer more aggressive. They use lab-grown human cancer cells and animal models to test drugs that block proteins that suppress normal prostate cell features and proteins that drive neuroendocrine changes. Some drugs already approved for other cancers and a drug in current prostate-cancer trials slow NEPC tumor growth, and combining them appears especially effective. The team aims to understand exactly how the combination kills NEPC cells so treatments can be moved toward patients.
Who could benefit from this research
Good fit: People with neuroendocrine prostate cancer—especially advanced or treatment-resistant cases and tumors showing loss of TP53 and RB1—would be the ideal candidates for related clinical testing.
Not a fit: Patients with typical hormone-sensitive prostate adenocarcinoma without neuroendocrine features or without TP53/RB1 alterations may not benefit from these specific approaches.
Why it matters
Potential benefit: If successful, this could lead to new combination therapies that better control or shrink NEPC tumors and provide treatment options for a disease that currently has few effective therapies.
How similar studies have performed: Preclinical studies in cells and animal models show promising anti-tumor activity for these drugs and combinations, but clinical testing specifically for NEPC is still limited.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Alumkal, Joshi James — University of Michigan at Ann Arbor
- Study coordinator: Alumkal, Joshi James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.